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Abstract
There is a disproportionate burden of gout in African-
Americans in the U.S. due to a higher disease
prevalence and lower likelihood of receiving urate-
lowering therapy (ULT), compared to Caucasians. There
is an absence of strong data as to whether the response
to ULT differs by race/ethnicity. BMC Musculoskeletal
Disorders recently published a secondary analyses of the
CONFIRMS trial, a large randomized controlled, double-
blind trial of 2,269 gout patients. The authors reported
that the likelihood of achieving the primary study
efficacy end-point of achieving serum urate < 6 mg/dl
was similar between African-Americans and Caucasians,
for all three treatment arms (Febuxostat 40 mg and
80 mg and allopurinol 300/200 mg). More importantly,
rates were similar in subgroups of patients with mild or
moderate renal insufficiency. Adverse event rates were
similar, as were the rates of gout flares. These findings
constitute a convincing evidence to pursue aggressive
ULT in gout patients, regardless of race/ethnicity. This
approach will likely help to narrow the documented
racial disparities in gout care.
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com/1471-2474/13/15
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Background
Gout is the most common inflammatory arthritis in the
U.S. that affects 4% of the general U.S. population [1].
The prevalence of gout is increasing in the U.S. [1-3],
r e l a t e da tl e a s tp a r t i a l l yt oarising rates of obesity and
hypertension [1]. Based on the National Health and
Nutrition Examination Survey (NHANES) 2007-2008, it
is estimated that 6 million Caucasians and 1.2 million
African-Americans in the U.S. have gout [1]. Gout pre-
sents with an extremely painful intermittent inflamma-
tory arthritis, which over time, progresses to a chronic,
deforming arthritis similar to rheumatoid arthritis. In
addition to causing musculoskeletal morbidity and urate
kidney stones, gout is an independent risk factor for car-
diovascular morbidity and mortality [4-7].
The treatment of gout includes two approaches, treat-
ment of acute episodes with medications that are anti-
inflammatory including non-steroidal anti-inflammatory
drugs (NSAIDs), colchicine or corticosteroids (oral, sys-
temic or intra-articular) and the long-term treatment of
hyperuricemia with medications that either reduce the
production of uric acid (urate-lowering therapy (ULT)
with xanthine oxidase inhibitors, allopurinol or febuxo-
stat) or increase the excretion of urate (uricosurics such
as probenecid [available in U.S.]; benzbromarone and
sulfinpyrazone [not available in U.S.]) [8]. Due to a
higher efficacy regardless of urate overproducer versus
underexcretor status, allopurinol or febuxostat is used
far more commonly than uricosurics. Despite availability
of efficacious treatments, less than 50% patients treated
with allopurinol, the commonest ULT, achieve the target
serum urate < 6 mg/dl [9,10] that is associated with
lower risk of gout flares, tophi and medical care costs
[9,11-15].
Racial Disparities in Gout Prevalence and Optimal
Treatment
African-Americans have a higher prevalence of gout com-
pared to Caucasians, ranging from 2-fold higher in an ear-
lier study [16] to 1.25-fold higher in a recent analyses of
NHANES 2007-08 [1]. An analysis of the 2002 US
National Ambulatory Medical Care Survey and National
Hospital Ambulatory Medical Care Survey found that
African-Americans with gout were less likely to receive
ULT compared to Caucasians [17]. The Institute of Medi-
cine has identified that racial disparities in health care are
common and that they are unacceptable [18]. Specifically,
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quality of healthcare across a range of chronic conditions,
and these disparities are found across a range of clinical
settings, such as public and private hospitals. The report
suggested multifaceted approach to reducing and eliminat-
ing these disparities, including raising public and health
care professionals’ awareness of the problem, health sys-
tem interventions such as following published guidelines
and improving health care access, educational tools for
patients to improve participation in their care and deci-
sion-making and policy and regulatory strategies. The
higher prevalence of gout coupled with lower likelihood of
receiving ULT leads to a disproportionate morbidity of
gout in African-Americans in the U.S. It is not known to
what extent underutilization of ULT in African-Americans
with gout is due to socioeconomic factors, health care
insurance and access, distance to the nearest health care
facility, patient preference, health literacy or health care
disparity.
CONFIRMS trial and Implications of Race/Ethnicity
Analyses
CONFIRMS was a Phase 3, double-blind randomized
controlled trial (RCT) that examined the comparative
efficacy and safety of febuxostat in 2,269 subjects, who
were randomized in 1:1:1 ratio to a daily dose of febuxo-
stat 40 mg, febuxostat 80 mg, or allopurinol 300 mg
(200 mg in patients with moderate renal impairment)
[13]. In a recent article published in BMC Musculoskele-
tal Disorders, Wells et al., conducted a secondary analy-
sis of the CONFIRMS trial, analyzing the efficacy and
safety outcomes for African-Americans (10%) versus
Caucasians (82%) enrolled in the trial [19]. They
reported that febuxostat at both doses as well as allo-
purinol at the 300/200 mg dose was equally efficacious
in achieving target serum urate < 6 mg/dl in both Afri-
can-Americans as compared to Caucasians, as well as in
subgroups of patients with mild renal insufficiency or
moderate renal insufficiency. The risk of gout flares and
the safety profile also seemed comparable between
African-Americans and Caucasians, i.e., similar propor-
tions reported at least one adverse event. Febuxostat
80 mg dose was more efficacious than 40 mg dose and
allopurinol 300/200 mg dose. However, the low dose of
allopurinol used in this study is effective in achieving
target serum urate < 50% gout patients [20], and is con-
sidered suboptimal as per the current state-of-the-art
gout treatment, where titration to the maximum
approved dose of 800 mg in the U.S. is recommended,
since the rate of allopurinol hypersensitivity seems to be
independent of allopurinol dose used [21], contrary to
what was previously suspected. An interesting observa-
tion, not discussed by authors, was that a lower propor-
tion of African-Americans had liver function test
abnormality (ALT elevation 2-times or higher, 2% vs.
13%, respectively) compared to Caucasians; however,
these data were provided as an aggregate and not by
treatment group and the rate of AST elevations seemed
similar. Another observation was that febuxostat 40 mg
was associated with significantly lower rates of achieving
target serum urate < 6 mg/dl in African-Americans than
Caucasians (38% vs. 55%, p = 0.046). The authors attri-
bute this, at least partially, to lower compliance with
Febuxostat 40 mg in African-Americans compared to
Caucasians (66% vs. 82%), greater for this treatment arm
than the other two (febuxostat 80 mg and allopurinol).
This is the first large randomized gout trial, for which
separate analyses have been performed by race. It is reas-
suring to see that the chances of successful treatment
with ULT are not different between African-Americans
and Caucasians. These findings have significant implica-
tions. They support the notion that if treated optimally,
both African-Americans and Caucasians with gout
respond similarly to ULT. More importantly, the safety
seemed similar in African-Americans and Caucasians
with gout, and a possibility of lower risk of liver toxicity
in African-Americans, which should be investigated
further in future studies. The results of this study provide
at least one way to reduce racial disparities in heath care
of patients with gout, i.e., by increasing awareness of the
public and providers’ that patients’ race/ethnicity does
not impact the efficacy and safety of ULT in gout. Evi-
dence-based gout quality indicators published 7 years ago
emphasize the importance of achieving target serum
urate < 6 mg/dl and using ULT as the main treatment
strategy in gout [22].
What is known about racial disparities and their elimi-
nation in other musculoskeletal disorders? Racial [23,24]
disparities in joint arthroplasty have been demonstrated
with African Americans and Hispanics with lower utiliza-
tion rates of knee and hip arthroplasty. A recent study
also indicates smaller gains in well-being and pain/func-
tional improvements after total joint arthroplasty in
African Americans compared to Caucasians [25]. Fewer
black patients (16%) with rheumatoid arthritis preferred
aggressive treatment compared with white patients (51%)
[26]. To our knowledge, very limited literature exists
regarding how to best eliminate these disparities. It
seems likely that increasing patient awareness of gout
and its effective treatments and institution of aggressive
treatment of gout in African Americans are two strategies
that are likely to be most helpful first steps in addressing
health disparities in gout.
Conclusions: What is the take home message?
This study provides the evidence for the first time that
ULT in gout patients is equi-efficacious in African-
Americans and Caucasians in a randomized trial. The
Singh BMC Medicine 2012, 10:15
http://www.biomedcentral.com/1741-7015/10/15
Page 2 of 4caveats of healthier population effect, Hawthorne effect,
generalization of findings from group level to indivi-
duals, and differences in health behaviors between
patients in clinical trials versus office practices that exist
in translating findings from every randomized trial to
clinical practice, exist in this case as well. Large sample
pharmacovigilance studies are needed to truly assess dif-
ferences in safety of ULT by race. Despite these limita-
tions, this study contributes significant new knowledge
in the area of comparative efficacy and safety of ULT in
gout between African-Americans and Caucasians. While
racial disparities in health care have complex etiology,
they are unacceptable. These data should encourage
physicians to aggressively treat both African-Americans
and Caucasians with gout.
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